You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

Displaying 201401 - 201410 of 207699 results
  1. Selection-driven plant metabolites for treatment of CNS diseases

    SBC: COARE BIOTECHNOLOGY, INC.            Topic: NCI

    DESCRIPTION (provided by applicant): Pancreatic ductal adenocarcinoma (PDAC) is a solid tumor and is the fourth leading cause of cancer-related death in the U.S. The 5-year survival rate of its victims is lt5%. There is increasing evidence that most solidtumors have a subpopulation of tumor-initiating cells termed cancer stem cells (CSCs). The inability to eradicate these CSCs is postulated to b ...

    SBIR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  2. Efficacy and Safety of an Aerosolized Recombinant Butyrylcholinesterase Pretreatm

    SBC: EXTEND BIOSCIENCES INC            Topic: NCI

    DESCRIPTION (provided by applicant): Cachexia is a complex syndrome characterized by involuntary weight loss and skeletal muscle wasting that leads to fatigue, weakness and a loss of appetite that is not reversed by increased caloric consumption. More thanhalf of all cancer patients develop cachexia and it is responsible for more than 40% of all cancer deaths. Numerous complications associated wit ...

    SBIR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  3. Development of OCT Imaging Adapter for Interstitial Tissue Imaging

    SBC: ALBUS IMAGING LLC            Topic: NCI

    DESCRIPTION (provided by applicant): In this application, we propose to conduct research to advance our patented technologies that identify early evidence of cardiovascular (CV) injury upon the receipt of cardiotoxic chemotherapy for breast cancer patients. For these patients, the prevalence of cardiovascular events including heart failure (HF) is 18% - 22%, and represents the second leading cause ...

    SBIR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  4. Detection and Alerting System for Seizure Onset (DASSO)

    SBC: WEINBERG MEDICAL PHYSICS, INC.            Topic: NCI

    DESCRIPTION (provided by applicant): We wish to improve treatment for patients with deep-seated brain tumors. With the help of the MRI-guided and nanoparticle-enabled system we are constructing, therapeutic access to these tumors will be provided through the delicate nooks, crannies, and membranes of the skull. In preliminary studies, we have demonstrated the ability to bypass the blood-brain barr ...

    SBIR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  5. A Device to Quantify Sweat of Single Sweat Glands to Diagnose Neuropathy

    SBC: PAPIVAX, LLC            Topic: NCI

    DESCRIPTION (provided by applicant): Treatment of Human papillomavirus (HPV) infections is a major unmet medical need. Importantly, the licensed HPV vaccines are not able to clear existing infections, and there are now multiple FDA-approved tests to detecthigh risk HPV DNA, and specifically HPV16. As these HPV DNA tests are widely implemented, large numbers of infected patients are being identifie ...

    SBIR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  6. The Development of TLR Antagonists for Therapy of Hepatic Fibrosis and Cirrhosis

    SBC: DIAGNOLOGIX, LLC            Topic: NCI

    Abstract There is an unmet need for cost-efficient technologies for high purity isolation of rare circulating tumor cells (CTCs) from blood. An ideal isolation technique should be able to meet the following criteria: (a) minimal processing time; (b) low final sample volume; (c) isolation from large blood volume; (d) low carryover of leukocytes and blood components; (e) high cell viability; (f) com ...

    SBIR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  7. Automating Directly Observed Therapy as a Platform Technology

    SBC: METACLIPSE THERAPEUTICS CORP            Topic: NCI

    DESCRIPTION (provided by applicant): Triple negative breast cancer (TNBC), which includes tumors lacking estrogen, progesterone, and HER-2 receptor proteins, represents 15-20% of all breast cancer diagnoses in the US, and is one of the most challenging cancers for developing an effective therapy post tumor resection. Even with conventional radiation and chemotherapy regimens, patients have poor pr ...

    SBIR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  8. Monodispersed magnetic nanoparticles for improved diagnostic imaging. Phase II: S

    SBC: CONFLUENCE LIFE SCIENCES, INC.            Topic: NCI

    DESCRIPTION (provided by applicant): Pancreatic cancer (PC) is the fourth leading cause of death from cancer in the US. Treatment options for this disease are extremely limited and prognosis is poor. At present, less than 6% of PC patients are alive afterfive years with an average survival time following diagnosis of 4-6 months, which is among the lowest for all cancers. It is clear that new thera ...

    SBIR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  9. Diabetes Prevention: Interactive DPP Curriculum for Virtual Small Group Delivery

    SBC: DISCOVERY GENOMICS, INC.            Topic: NCI

    DESCRIPTION (provided by applicant): Pancreatic cancer represents the 10th most common cancer diagnosis, yet the 4th most common estimated cause of death. The only potential curative therapy for pancreatic cancer is surgical resection; however, few patients have tumors which can be respected. Pancreatic ductal adenocarcinoma, which represents 90% of pancreatic cancers, is particularly aggressive, ...

    SBIR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  10. Low-Dose MRI-Compatible Molecular Breast Imaging Device

    SBC: EMPIRE GENOMICS LLC            Topic: NCI

    DESCRIPTION (provided by applicant): Multiple myeloma is a malignant plasma cell cancer that is increasing in frequency in today's aging population. While new combination therapies have improved the outcome of treatment, many patients fail to achieve a complete remission and ultimately the disease progresses. With these new treatments come higher associated toxicities and significant healthca ...

    SBIR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government